Payment overview · 2025
General Payments
$458.93
30 reported records · 9 companies
Healthcare provider profile · identity verified
Debra Ann Grayson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · COLUMBUS, OH · NPI 1356333785
Verified facts
What the public records show
CMS Open Payments records show Debra Ann Grayson, D.O. received $458.93 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 45.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.17 | 45.6% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $58.14 | 12.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.07 | 10.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.37 | 7.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $33.18 | 7.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.74 | 5.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.29 | 4.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.85 | 3.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.12 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $458.93 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $138.87 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $119.34 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $58.14 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.07 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $48.07 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.37 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $33.18 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $28.91 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $22.74 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.98 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.98 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.29 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 123 |
| Losartan Potassium | Losartan Potassium | 429 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 66 |
| Gabapentin | Gabapentin | 286 | 63 |
| Lisinopril | Lisinopril | 281 | 71 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 274 | 55 |
| Tramadol Hcl | Tramadol Hcl | 250 | 43 |
| Omeprazole | Omeprazole | 246 | 64 |
| Furosemide | Furosemide | 243 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 241 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 241 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 216 | 50 |
| Trazodone Hcl | Trazodone Hcl | 196 | 39 |
| Glipizide | Glipizide | 192 | 44 |
| Metformin Hcl | Metformin Hcl | 191 | 49 |
| Alprazolam | Alprazolam | 190 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 190 | 51 |
| Simvastatin | Simvastatin | 178 | 42 |
| Irbesartan | Irbesartan | 171 | 43 |
| Citalopram Hbr | Citalopram Hydrobromide | 157 | 42 |
| Amoxicillin | Amoxicillin | 154 | 95 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 146 | 24 |
| Naproxen | Naproxen | 136 | 23 |
| Metformin Hcl Er | Metformin Hcl | 129 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 127 | 13 |
| Potassium Chloride | Potassium Chloride | 125 | 33 |
| Cephalexin | Cephalexin | 122 | 71 |
| Metoprolol Tartrate | Metoprolol Tartrate | 118 | 27 |
| Sertraline Hcl | Sertraline Hcl | 116 | 32 |
| Ibuprofen | Ibuprofen | 112 | 27 |
| Azithromycin | Azithromycin | 111 | 73 |
| Lorazepam | Lorazepam | 106 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 105 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 53 |
| Methylprednisolone | Methylprednisolone | 97 | 71 |
| Bupropion Xl | Bupropion Hcl | 91 | 20 |
| Eliquis | Apixaban | 89 | 19 |
| Carvedilol | Carvedilol | 86 | 24 |
| Montelukast Sodium | Montelukast Sodium | 84 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 81 | 14 |
| Ozempic | Semaglutide | 81 | 14 |
| Meloxicam | Meloxicam | 79 | 21 |
| Diazepam | Diazepam | 76 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 57 | 17 |
| Spironolactone | Spironolactone | 57 | 15 |
| Mirtazapine | Mirtazapine | 56 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 29 |
| Atenolol | Atenolol | 52 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 52 | 16 |
| Fluconazole | Fluconazole | 49 | 26 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 47 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 13 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Famotidine | Famotidine | 45 | 11 |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | 11 |
| Donepezil Hcl | Donepezil Hcl | 44 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | suppressed |
| Estradiol | Estradiol | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | suppressed |
| Celecoxib | Celecoxib | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | suppressed |
| Prednisone | Prednisone | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 20 |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 14 |
| Linzess | Linaclotide | 29 | suppressed |
| Allopurinol | Allopurinol | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 13 |
| Nifedipine Er | Nifedipine | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 24 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 20 | 11 |
| Rybelsus | Semaglutide | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Glyburide | Glyburide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Tobramycin | Tobramycin | 16 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 15 | suppressed |
| Premarin | Estrogens, Conjugated | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Pimozide | Pimozide | 14 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Tri-Linyah | Norgestimate-Ethinyl Estradiol | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $458.93 · 30 records | ABBVIE INC. | AIRSUPRA, Auvelity, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, LINZESS, MOUNJARO, NURTEC ODT, QULIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error